|85.41||+0.1700||+0.20%||Vol 721.64K||1Y Perf 709.00%|
|Apr 9th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||96.67||Analyst Rating||Strong Buy 1.00|
|Potential %||13.18||Finscreener Ranking||★★★★★ 65.02|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★★ 65.49|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 83.62|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||2.48B||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||41.83||Earnings Date||3rd May 2021|
Today's Price Range
5 Year PE Ratio Range
|3 Years||2 062.28%|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||3rd May 2021|
|Estimated EPS Next Report||5.95|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.25M|
|Avg. Monthly Volume||1.62M|
|Avg. Quarterly Volume||1.98M|
Fulgent Genetics Inc. (NASDAQ: FLGT) stock closed at 85.41 per share at the end of the most recent trading day (a 0.2% change compared to the prior day closing price) with a volume of 724.39K shares and market capitalization of 2.48B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 139 people. Fulgent Genetics Inc. CEO is Ming Hsieh.
The one-year performance of Fulgent Genetics Inc. stock is 709%, while year-to-date (YTD) performance is 63.93%. FLGT stock has a five-year performance of %. Its 52-week range is between 10.27 and 189.89, which gives FLGT stock a 52-week price range ratio of 41.83%
Fulgent Genetics Inc. currently has a PE ratio of 10.90, a price-to-book (PB) ratio of 4.92, a price-to-sale (PS) ratio of 7.03, a price to cashflow ratio of 16.50, a PEG ratio of 2.32, a ROA of 53.77%, a ROC of 37.87% and a ROE of 64.99%. The company’s profit margin is 52.40%, its EBITDA margin is 49.00%, and its revenue ttm is $413.96 Million , which makes it $14.28 revenue per share.
Of the last four earnings reports from Fulgent Genetics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $5.95 for the next earnings report. Fulgent Genetics Inc.’s next earnings report date is 03rd May 2021.
The consensus rating of Wall Street analysts for Fulgent Genetics Inc. is Strong Buy (1), with a target price of $96.67, which is +13.18% compared to the current price. The earnings rating for Fulgent Genetics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Fulgent Genetics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Fulgent Genetics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 19.17, ATR14 : 17.44, CCI20 : -44.60, Chaikin Money Flow : -0.16, MACD : -3.42, Money Flow Index : 40.91, ROC : 3.93, RSI : 50.59, STOCH (14,3) : 47.55, STOCH RSI : 1.00, UO : 42.20, Williams %R : -52.45), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Fulgent Genetics Inc. in the last 12-months were: Han Lin Gao (Sold 1 609 shares of value $67 452 ), Jian Xie (Sold 83 519 shares of value $7 280 278 ), John C. Bolger (Option Excercise at a value of $103 794), John C. Bolger (Sold 32 825 shares of value $1 118 270 ), Paul Kim (Sold 301 646 shares of value $13 470 973 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.